Pharmanormal activities

When Monique Levy, one of the most-level-headed analysts in the pharma industry, calls attention to a mysterious phenomenon, you listen.

Editor's Desk: And the researchers go wild

Apple's ResearchKit could accelerate the pace at which industry approaches start-ups building products in the patient-facing part of health tech

Editor's Desk—Pill+: Now I'm a Believer

If you look at this as simply a tool to drive your brand, you've missed the point

Editor's Desk: Trials and innovations

How should pharma organize around adjacencies to therapeutics?

Editor's Desk: Whither the fast followers?

Will DIY and the mHealth movement be the catalysts driving change?

Disruption on display

As these 40 standouts show, the industry is ready to move forward

Adherence is in the behavior

There needs to be a greater effort put into the issue of adherence. What can academia, providers, pharma and payers do to address this pressing need?

Marketing to Millennials

Gen Y wants companies to stand for "Important missions and values"

Down... but not out

Satisfaction levels among pharma-based respondents fell, but didn't exactly tank

Live, listen and learn

Companies are realizing that they need to be more attuned to their audience


Pharma continues to struggle with its image. Exhibit A is the public debate around the price of, and access to, new and innovative meds. As countless transformative technologies hit market, has industry done enough to anchor its permission to innovate? To provide a closer look at trends affecting trust over the past year, MM&M presents this e-book, "The 2015 Edelman Trust Barometer." Click here.

Email Newsletters